MHRA Drug Safety Update

10 April 2025

Fezolinetant▼(Veoza): risk of liver injury; new recommendations to minimise risk

Fezolinetant treatment is associated with a risk of drug induced liver disease. New recommendations have been introduced to minimise this risk. Liver function should be monitored before and during treatment in all patients taking fezolinetant. Fezolinetant should be avoided in patients with known liver disease or at a higher risk of liver disease.

It's easy to report

Report a suspected adverse drug reaction online
or download the Yellow Card app

REPORT ONLINE

Thank you,

The Medicines and Healthcare products Regulatory Agency

If you would like to share this with a friend or colleague, hit the Forward button or send them this link to view the email in a browser.

Unsubscribe or change your email address at any time on your subscriber preferences page.

If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.

All other enquiries can be directed to email.support@mhra.gov.uk.

This is an automatically generated email. Please do not reply directly to this notification.
This service is provided to you at no charge by the Medicines and Healthcare products Regulatory Agency.